Through the use of MRI image data, RenalVue can electronically evaluate renal conditions and therapy impact on kidneys more efficiently and effectively than conventional renal-assessment tools.
Atherosclerotic renal artery stenosis (aRAS) is a recognized cause of chronic kidney disease (CKD) and end-stage renal disease. It also is strongly associated with increased risks for cardiac events and mortality.
Procedures such as stent placement and surgical bypass are used to treat aRAS in hopes of reducing kidney-related and cardiovascular morbidity and mortality. But less than half of the 45,000 people who undergo these procedures each year in the United States experience significant improvement in kidney function, the most significant indicator of subsequent survival. This is due to an incomplete understanding of the pathophysiology of aRAS-associated CKD and the current inability to accurately measure the functional capability of kidney tissue distal to an aRAS lesion.
Researchers at Wake Forest developed systems, methods and computer-program products that can provide an automated analysis of renal MRI images to help doctors better determine whether a patient with aRAS is likely to benefit or not benefit from a particular medical or procedural therapy. The technology also can display rendered kidney tissue maps and/or MRI images showing oxygenation, blood flow, perfusion and other indicators of kidney function to assist doctors in their assessments.
- Provides more kidney-function data and requires less manual analysis than existing renal-evaluation systems.
- Can measure various kidney functions, generate various types of images and analyze risk evaluation for various therapies.
- Can provide detailed renal-risk report within 24 hours of patient’s MRI session.
- Can be configured to provide rapid analysis (within two hours of patient’s MRI session).
Stage of Development
The utility of the imaging techniques has been demonstrated on humans in a clinical setting and it based upon related techniques in cardiac imaging that are supported by over 15 years of clinical science.
Greg Hundley, MD
Cardiology and Radiology
Craig A. Hamilton, PhD
Matthew S. Edwards, MD
Vascular and Endovascular Surgery
Michael Vito Rocco, MD
U.S. Patent Application No. PCT/US2012/059456
Hall ME, et al. Chronic diuretic therapy attenuates renal BOLD magnetic resonance response to an acute furosemide stimulus. Journal of Cardiovascular Magnetic Resonance. 2014, February
Reference #: WFU 11-67